Surmodics ROE 2006-2019 | SRDX

Current and historical return on equity (ROE) values for Surmodics (SRDX) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Surmodics ROE for the three months ending June 30, 2019 was 4.87%.
Surmodics ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2019-06-30 $0.00B $0.12B 0.88%
2019-03-31 $-0.00B $0.12B -2.68%
2018-12-31 $-0.00B $0.11B -1.80%
2018-09-30 $-0.01B $0.11B -4.52%
2018-06-30 $-0.00B $0.11B -2.70%
2018-03-31 $0.00B $0.11B 0.90%
2017-12-31 $0.00B $0.11B 0.00%
2017-09-30 $0.00B $0.11B 3.66%
2017-06-30 $0.01B $0.11B 6.48%
2017-03-31 $0.01B $0.11B 9.39%
2016-12-31 $0.01B $0.11B 9.62%
2016-09-30 $0.01B $0.11B 10.89%
2016-06-30 $0.01B $0.10B 9.25%
2016-03-31 $0.01B $0.10B 9.57%
2015-12-31 $0.01B $0.10B 12.15%
2015-09-30 $0.01B $0.09B 13.75%
2015-06-30 $0.01B $0.09B 14.61%
2015-03-31 $0.01B $0.09B 14.40%
2014-12-31 $0.01B $0.08B 13.08%
2014-09-30 $0.01B $0.10B 12.83%
2014-06-30 $0.01B $0.10B 15.18%
2014-03-31 $0.01B $0.09B 13.98%
2013-12-31 $0.02B $0.09B 15.67%
2013-09-30 $0.02B $0.09B 15.27%
2013-06-30 $0.01B $0.10B 14.21%
2013-03-31 $0.01B $0.10B 12.56%
2012-12-31 $0.01B $0.10B 9.80%
2012-09-30 $0.01B $0.10B 8.24%
2012-06-30 $-0.01B $0.15B -7.60%
2012-03-31 $-0.01B $0.15B -6.81%
2011-12-31 $-0.01B $0.14B -6.73%
2011-09-30 $-0.02B $0.14B -12.54%
2011-06-30 $-0.02B $0.16B -14.19%
2011-03-31 $-0.03B $0.15B -16.95%
2010-12-31 $-0.03B $0.16B -17.60%
2010-09-30 $-0.02B $0.15B -12.37%
2010-06-30 $0.00B $0.18B 2.30%
2010-03-31 $0.01B $0.18B 5.22%
2009-12-31 $0.01B $0.18B 7.68%
2009-09-30 $0.04B $0.17B 23.03%
2009-06-30 $0.03B $0.17B 21.59%
2009-03-31 $0.04B $0.16B 23.06%
2008-12-31 $0.04B $0.16B 24.49%
2008-09-30 $0.02B $0.14B 10.58%
2008-06-30 $0.00B $0.15B 1.44%
2008-03-31 $0.00B $0.14B 2.19%
2007-12-31 $0.00B $0.14B 2.99%
2007-09-30 $0.00B $0.13B 2.99%
2007-06-30 $0.02B $0.14B 17.45%
2007-03-31 $0.02B $0.13B 17.52%
2006-12-31 $0.02B $0.14B 13.92%
2006-09-30 $0.02B $0.15B 14.31%
2006-06-30 $0.02B $0.14B 14.34%
2006-03-31 $0.02B $0.13B 15.16%
2005-12-31 $-0.01B $0.12B -6.35%
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.607B $0.081B
SurModics, Inc. is a leading provider of surface modification technologies in the areas of biocompatibility, site specific drug delivery, biological cell encapsulation, and medical diagnostics. SurModics partners with the world's foremost medical device, pharmaceutical and life science companies to bring innovation together for better patient outcomes. Recent collaborative efforts include the implementation of SurModics' Bravo drug delivery polymer matrix as a key component of the first-to-market drug-eluting coronary stent. SurModics is also active in the ophthalmology market with a sustained drug delivery system that is currently in human trials for treatment of retinal disease. A significant portion of SurModics' revenue is generated by royalties earned from the sale of our customers' commercial products.
Stock Name Country Market Cap PE Ratio
Medtronic (MDT) Ireland $145.155B 20.38
Abbott Laboratories (ABT) United States $144.891B 27.24
Stryker (SYK) United States $80.414B 27.81
Boston Scientific (BSX) United States $53.574B 25.99
Baxter (BAX) United States $44.796B 27.16
EssilorLuxottica Societe Anonyme (ESLOY) France $32.784B 0.00
Zimmer Biomet Holdings (ZBH) United States $28.311B 18.12
Coloplast (CLPBY) Denmark $25.596B 40.86
Lonza Group Ag (LZAGY) Switzerland $25.166B 0.00
Terumo (TRUMY) Japan $23.897B 29.82
Smith & Nephew SNATS (SNN) United Kingdom $20.556B 0.00
ResMed (RMD) United States $18.755B 35.74
Sunny Optical Technology (SNPTF) China $16.014B 0.00
Bio-Rad Laboratories (BIO) United States $9.968B 53.44
Insulet (PODD) United States $9.367B 555.07
Perrigo (PRGO) Ireland $7.321B 13.49
Canopy Growth (CGC) Canada $6.992B 0.00
Hill-Rom Holdings (HRC) United States $6.758B 20.15
Haemonetics (HAE) United States $6.423B 48.47
William Demant Holdings (WILYY) Denmark $5.988B 0.00
GN STORE NORD (GNNDY) Denmark $5.322B 27.49
Shandong Weigao Medical Polymer (SHWGF) China $4.296B 0.00
Aurora Cannabis (ACB) Canada $3.868B 0.00
GW Pharmaceuticals (GWPH) United Kingdom $3.717B 0.00
Neogen (NEOG) United States $3.401B 56.90
NuVasive (NUVA) United States $3.312B 26.40
ICU Medical (ICUI) United States $3.149B 20.43
Hutchison China MediTech (HCM) Hong Kong, SAR China $2.522B 0.00
Quidel (QDEL) United States $2.431B 24.14
Agios Pharmaceuticals (AGIO) United States $1.998B 0.00
National Vision Holdings (EYE) United States $1.919B 41.42
Cardiovascular Systems (CSII) United States $1.617B 0.00
Aphria (APHA) $1.368B 0.00
VAREX IMAGING (VREX) United States $1.117B 25.74
AtriCure (ATRC) United States $1.022B 0.00
Phibro Animal Health (PAHC) United States $0.885B 14.39
Eagle Pharmaceuticals (EGRX) United States $0.847B 21.60
NanoString Technologies (NSTG) United States $0.779B 0.00
PetIQ (PETQ) United States $0.778B 18.37
Omeros (OMER) United States $0.764B 0.00
Lantheus Holdings (LNTH) United States $0.742B 19.50
LeMaitre Vascular (LMAT) United States $0.670B 39.72
Cerus (CERS) United States $0.633B 0.00
MacroGenics (MGNX) United States $0.562B 0.00
Quanterix (QTRX) United States $0.554B 0.00
OraSure Technologies (OSUR) United States $0.510B 23.60
TG Therapeutics (TGTX) United States $0.507B 0.00
Meridian Bioscience (VIVO) United States $0.423B 13.21
Owens & Minor (OMI) United States $0.406B 12.17
Zynex (ZYXI) United States $0.384B 40.79
Utah Medical Products (UTMD) United States $0.342B 25.05
BioLife Solutions (BLFS) United States $0.329B 101.06
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.321B 0.00
United Health Products (UEEC) United States $0.242B 0.00
Bovie Medical (APYX) United States $0.223B 0.00
Vapotherm (VAPO) United States $0.179B 0.00
Rockwell Medical (RMTI) United States $0.153B 0.00
Cytosorbents (CTSO) United States $0.148B 0.00
Female Health (VERU) United States $0.137B 0.00
Fonar (FONR) United States $0.131B 9.16
InfuSystems Holdings (INFU) United States $0.129B 0.00
Liberty Health Sciences (LHSIF) $0.101B 0.00
Chembio Diagnostics (CEMI) United States $0.096B 0.00
Chimerix (CMRX) United States $0.088B 0.00
United-Guardian (UG) United States $0.086B 20.46
Nephros (NEPH) United States $0.077B 0.00
MTech Acquisition (KERN) United States $0.063B 0.00
MRI Interventions (MRIC) United States $0.059B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.054B 0.00
ImmuCell (ICCC) United States $0.040B 0.00
Surface Oncology (SURF) United States $0.037B 0.00
Trinity Biotech (TRIB) Ireland $0.024B 0.00
Senestech (SNES) United States $0.023B 0.00
GUARDION HEALTH (GHSI) United States $0.019B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.011B 0.00
Myomo (MYO) United States $0.010B 0.00
Capricor Therapeutics (CAPR) United States $0.010B 0.00
Valeritas Holdings (VLRX) United States $0.007B 0.00
Akers Biosciences Inc (AKER) United States $0.005B 0.00
NeuroMetrix (NURO) United States $0.003B 0.00